- Home
- ICE vs DMAC Comparison
ICE vs DMAC Comparison
Compare ICE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICE
- DMAC
- Stock Information
- Founded
- ICE 2000
- DMAC 2000
- Country
- ICE United States
- DMAC United States
- Employees
- ICE N/A
- DMAC N/A
- Industry
- ICE Investment Bankers/Brokers/Service
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ICE Finance
- DMAC Health Care
- Exchange
- ICE Nasdaq
- DMAC Nasdaq
- Market Cap
- ICE 99.5B
- DMAC 310.1M
- IPO Year
- ICE 2005
- DMAC N/A
- Fundamental
- Price
- ICE $172.62
- DMAC $6.89
- Analyst Decision
- ICE Buy
- DMAC Strong Buy
- Analyst Count
- ICE 13
- DMAC 3
- Target Price
- ICE $194.38
- DMAC $12.33
- AVG Volume (30 Days)
- ICE 2.5M
- DMAC 448.5K
- Earning Date
- ICE 10-30-2025
- DMAC 11-12-2025
- Dividend Yield
- ICE 1.12%
- DMAC N/A
- EPS Growth
- ICE 28.91
- DMAC N/A
- EPS
- ICE 5.21
- DMAC N/A
- Revenue
- ICE $9,688,000,000.00
- DMAC N/A
- Revenue This Year
- ICE $8.72
- DMAC N/A
- Revenue Next Year
- ICE $5.57
- DMAC N/A
- P/E Ratio
- ICE $33.02
- DMAC N/A
- Revenue Growth
- ICE 9.95
- DMAC N/A
- 52 Week Low
- ICE $142.29
- DMAC $3.19
- 52 Week High
- ICE $189.35
- DMAC $7.49
- Technical
- Relative Strength Index (RSI)
- ICE 38.17
- DMAC 64.40
- Support Level
- ICE $170.25
- DMAC $6.82
- Resistance Level
- ICE $176.59
- DMAC $7.41
- Average True Range (ATR)
- ICE 2.42
- DMAC 0.43
- MACD
- ICE -0.10
- DMAC 0.01
- Stochastic Oscillator
- ICE 30.63
- DMAC 75.32
About ICE Intercontinental Exchange Inc.
Intercontinental Exchange is a vertically integrated operator of financial exchanges and provides ancillary data products. Though the company is probably best known for its ownership of the New York Stock Exchange, which it acquired in 2013, ICE operates a large derivatives exchange, too. The company's largest commodity futures product is the ICE Brent crude futures contract. In addition to the exchanges business, which is about 54% of net revenue, Intercontinental Exchange has used a series of acquisitions to create its mortgage technology business (22% of net revenue) and fixed-income and data services segment (24% of net revenue).
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.